Protagonist director sells shares after option exercise
Protagonist Therapeutics director William D. Waddill exercised stock options and sold shares in a coordinated transaction.
Rhea-AI Filing Summary
Protagonist Therapeutics director William D. Waddill exercised stock options and sold shares in a coordinated transaction. He exercised 9,000 shares of Common Stock at $11.80 per share, then sold 9,000 shares in an open-market sale at $99.64 per share.
After these transactions, he directly holds 7,825 shares of Common Stock and 3,000 stock options remain outstanding, with the options expiring on June 6, 2029. The filing notes the trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026, indicating they were scheduled in advance.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 9,000 shares ($791K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Waddill William D.
Role
Director
Sold
9,000 shs ($897K)
Approx. gross sale proceeds
$897K
Approx. exercise cost
$106K
Approx. pre-tax spread
$791K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 9,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 9,000 | $11.80 | $106K |
| Sale | Common Stock | 9,000 | $99.64 | $897K |
Holdings After Transaction:
Stock Option (right to buy) — 3,000 contracts (Direct);
Common Stock — 7,825 shares (Direct)
Footnotes (2)
- F1. The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 27, 2026.
- F2. These stock options are fully vested.
Key Figures
Shares sold: 9,000 shares
Sale price: $99.64 per share
Options exercised: 9,000 shares
+5 more
8 metrics
Shares sold
9,000 shares
Common Stock sold in open-market transaction
Sale price
$99.64 per share
Price for 9,000 Common Stock shares sold
Options exercised
9,000 shares
Common Stock acquired via option exercise
Exercise price
$11.80 per share
Stock option exercise price for 9,000 shares
Shares held after
7,825 shares
Common Stock directly owned following transactions
Options remaining
3,000 options
Stock options outstanding after exercise
10b5-1 plan adoption date
February 27, 2026
Date reporting person adopted Rule 10b5-1 plan
Option expiration
June 6, 2029
Expiration date of remaining stock options
Key Terms
Rule 10b5-1 plan, open-market sale, Stock Option (right to buy), fully vested
4 terms
Rule 10b5-1 plan regulatory
"transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
open-market sale financial
"transaction_action: "open-market sale" for 9,000 Common Stock shares"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)" with underlying Common Stock"
fully vested financial
"These stock options are fully vested."
FAQ
What insider transaction did PTGX director William D. Waddill report?
Director William D. Waddill reported exercising stock options and selling shares of Protagonist Therapeutics common stock. He exercised 9,000 options and sold 9,000 shares in an open-market transaction, reflecting a typical exercise-and-sell pattern for equity compensation rather than a standalone open-market purchase.
What stock options did the PTGX director exercise in this Form 4 filing?
He exercised stock options covering 9,000 shares of Protagonist Therapeutics common stock at an exercise price of $11.80 per share. These options were fully vested, and 3,000 options remain outstanding after the transaction, with an expiration date of June 6, 2029.
Were the PTGX insider transactions made under a Rule 10b5-1 plan?
Yes. The Form 4 states the transactions were effected under a Rule 10b5-1 trading plan adopted on February 27, 2026. Such pre-arranged plans schedule trades in advance, which can reduce the significance of trade timing as a signal of the insider’s current market view.
What does the Form 4 reveal about remaining PTGX stock options for the director?
After exercising 9,000 options, the director has 3,000 stock options still outstanding. These options are fully vested and carry a stated expiration date of June 6, 2029, giving him additional potential to acquire Protagonist Therapeutics shares in the future if he elects to exercise.
AI-generated analysis. How Rhea-AI works. Not financial advice.
